KHCM
MYGN icon

Kettle Hill Capital Management’s Myriad Genetics MYGN Stock Holding History

Kettle Hill Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-88,355
Closed -$2.41M – 53
2019
Q4 		$2.41M Buy
+88,355
New +$2.43M 0.61% 26

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kettle Hill Capital Management's MYGN Position: Q1 2020 in Review

Kettle Hill Capital Management sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 88,355 shares — an estimated $2.41M sold.

Kettle Hill Capital Management first reported a position in MYGN in Q4 2019 and held it in 1 quarter. The position peaked at $2.41M in Q4 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Kettle Hill Capital Management reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • Kettle Hill Capital Management sold 88,355 Myriad Genetics shares in Q1 2020, an estimated $2.41M.
  • Kettle Hill Capital Management first reported a position in Myriad Genetics in Q4 2019 and held it in 1 quarter.
  • Kettle Hill Capital Management's Myriad Genetics position peaked at $2.41M in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Kettle Hill Capital Management's 13F filing for Q1 2020, filed 15 May 2020.